Thomas Andrew Rowland, SVP and head of established brands at ANI Pharmaceuticals Inc (NASDAQ: ANIP), executed a sale of 4,772 shares of common stock on March 11, 2026. The transaction was completed at $74.91 per share and brought the total value of the disposition to $357,470.
Following the March 11 sale, Rowland retains direct ownership of 38,730 shares of ANI Pharmaceuticals. The transaction was reported in a Form 4 filing with the Securities and Exchange Commission.
Market context noted in the filing shows the stock trading at $70.36 at the time of the report, with the company carrying a price-to-earnings ratio of 21.37. The filing also cited a recent 44% increase in revenue over the last twelve months.
In a separate set of company disclosures, ANI Pharmaceuticals released fourth-quarter 2025 financial results that outpaced consensus expectations. The company reported earnings per share of $2.33, compared with analyst estimates of $1.97 - a positive surprise quantified at 18.27%. Revenue for the quarter totaled $247.1 million, above the anticipated $232.37 million.
Despite the stronger-than-expected EPS and revenue results, ANI Pharmaceuticals' shares experienced a premarket decline on the report. The juxtaposition of an earnings beat and an immediate negative market response is highlighted in company disclosures and public filings.
The Form 4 filing and accompanying notes reference third-party analysis indicating that the stock appears undervalued at current levels, and that net income is expected to grow this year. The filing points readers toward additional research resources, noting that a comprehensive Pro Research Report is available for ANIP and more than 1,400 U.S. stocks.
Promotional materials included in the public information also describe ProPicks AI, a monthly evaluation tool that assesses ANIP among thousands of companies using over 100 financial metrics. The materials state the AI evaluates fundamentals, momentum, and valuation, and cite past winners such as Super Micro Computer (+185%) and AppLovin (+157%) as examples provided by the service.
Investors and market participants are watching both insider activity and the company’s recent results as ANI Pharmaceuticals moves forward in the current market environment.